Kyverna publishes AAN presentation on miv-cel data in stiff person syndrome, gMG

• Kyverna highlighted new registrational data for CD19 CAR T mivocabtagene autoleucel, positioning it for potential first approval in autoimmune disease.
• In KYSA-8 stiff person syndrome trial (n=26), primary endpoint was met with 46% median improvement in timed 25-foot walk at week 16 (P=0.0003).
• Kyverna reported 81% of patients achieved clinically meaningful improvement of at least 20% on timed 25-foot walk at week 16.
• All 26 patients remained free of immunomodulatory or immunosuppressant therapies for stiff person syndrome as of week 16 through last follow-up.
• Safety profile showed no high-grade CRS or ICANS; any-grade CRS occurred in 24 patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kyverna Therapeutics Inc. published the original content used to generate this news brief on April 22, 2026, and is solely responsible for the information contained therein.